Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease

References

• Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, Brechbiel MW. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004; 10:7834-41; PMID:15585615; http://dx.doi.org/10.1158/1078-0432.CCR-04-1226
   PubMed Web of Science ®Google Scholar
• Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, Brechbiel MW. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 2005; 20:557-68; PMID:16248771; http://dx.doi.org/10.1089/cbr.2005.20.557
   PubMed Web of Science ®Google Scholar
• Milenic DE, Baidoo KE, Shih JH, Wong KJ, Brechbiel MW. Evaluation of platinum chemotherapy in combination with HER2-targeted alpha-particle radiation. Cancer Biother Radiopharm 2013; 28:441-9; PMID:23758610; http://dx.doi.org/10.1089/cbr.2012.1423
   PubMed Web of Science ®Google Scholar
• Milenic DE, Garmestani K, Brady ED, Albert PS, Abdulla A, Flynn J, Brechbiel MW. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin Cancer Res 2007; 13:1926-35; PMID:17363549; http://dx.doi.org/10.1158/1078-0432.CCR-06-2300
   PubMed Web of Science ®Google Scholar
• Milenic DE, Garmestani K, Brady ED, Baidoo KE, Albert PS, Wong KJ, Flynn J, Brechbiel MW. Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin Cancer Res 2008; 14:5108-15; PMID:18698028; http://dx.doi.org/10.1158/1078-0432.CCR-08-0256
   PubMed Web of Science ®Google Scholar
• Howell RW, Azure MT, Narra VR, Rao DV. Relative biological effectiveness of alpha-particle emitters in vivo at low doses. Radiat Res 1994; 137:352-60; PMID:8146279; http://dx.doi.org/10.2307/3578710
   PubMed Web of Science ®Google Scholar
• Baidoo KE, Milenic DE, Brechbiel MW. Methodology for labeling proteins and peptides with lead-212 (212Pb). Nucl Med Biol 2013; 40:592-9; PMID:23602604; http://dx.doi.org/10.1016/j.nucmedbio.2013.01.010
   PubMed Web of Science ®Google Scholar
• Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, Carlise R, Bunch P, Yoder D, Alvarez R. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm 2014; 29:12-7; PMID:24229395; http://dx.doi.org/10.1089/cbr.2013.1531
   PubMed Web of Science ®Google Scholar
• Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol Cancer Ther 2012; 11:639-48; PMID:22238365; http://dx.doi.org/10.1158/1535-7163.MCT-11-0671
   PubMed Web of Science ®Google Scholar
• Yong KJ, Milenic DE, Baidoo KE, Kim YS, Brechbiel MW. Gene expression profiling upon (212) Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model. Cancer Med 2013; 2:646-53; PMID:24403230
   PubMed Web of Science ®Google Scholar
• Agus DB, Bunn PA, Jr., Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 2000; 27:53-63; discussion 92-100.
   PubMed Web of Science ®Google Scholar
• Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990; 45:457-61; PMID:1968437; http://dx.doi.org/10.1002/ijc.2910450314
   PubMed Web of Science ®Google Scholar
• Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001; 19:554-68; PMID:11458821; http://dx.doi.org/10.1081/CNV-100103852
   PubMed Web of Science ®Google Scholar
• Lanitis E, Dangaj D, Hagemann IS, Song DG, Best A, Sandaltzopoulos R, Coukos G, Powell DJ, Jr. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS One 2012; 7:e49829; PMID:23189165
   PubMed Web of Science ®Google Scholar
• Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11:689-708; PMID:15613446; http://dx.doi.org/10.1677/erc.1.00600
   PubMed Web of Science ®Google Scholar
• Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002; 94:1593-611; PMID:11920518; http://dx.doi.org/10.1002/cncr.10372
   PubMed Web of Science ®Google Scholar
• Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001; 13:506-13; PMID:11673692; http://dx.doi.org/10.1097/00001622-200111000-00014
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45; PMID:15269313; http://dx.doi.org/10.1056/NEJMoa033025
   PubMed Web of Science ®Google Scholar
• Humblet Y. Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin Pharmacother 2004; 5:1621-33; PMID:15212612; http://dx.doi.org/10.1517/14656566.5.7.1621
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040-8; PMID:18003960; http://dx.doi.org/10.1056/NEJMoa071834
   PubMed Web of Science ®Google Scholar
• Guo Y, Parry JJ, Laforest R, Rogers BE, Anderson CJ. The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer. J Nucl Med 2013; 54:1621-9; PMID:23873478; http://dx.doi.org/10.2967/jnumed.112.118539
   PubMed Web of Science ®Google Scholar
• Liu Z, Ma T, Liu H, Jin Z, Sun X, Zhao H, Shi J, Jia B, Li F, Wang F. Lu-Labeled Antibodies for EGFR-Targeted SPECT/CT Imaging and Radioimmunotherapy in a Preclinical Head and Neck Carcinoma Model. Mol Pharm 2014; 11: 800-807; http://dx.doi.org/10.1021/mp4005047
   Web of Science ®Google Scholar
• Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, Brechbiel MW. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 2008; 23:619-31; PMID:18999934; http://dx.doi.org/10.1089/cbr.2008.0493
   PubMed Web of Science ®Google Scholar
• Nayak TK, Garmestani K, Milenic DE, Baidoo KE, Brechbiel MW. HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. PLoS One 2011; 6:e18198; PMID:21464917; http://dx.doi.org/10.1371/journal.pone.0018198
   PubMed Web of Science ®Google Scholar
• Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, Brechbiel MW. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A’’-DTPA-cetuximab. Eur J Nucl Med Mol Imaging 2010; 37:1368-76; PMID:20155263; http://dx.doi.org/10.1007/s00259-009-1370-z
   PubMed Web of Science ®Google Scholar
• Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, van Dongen GA. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005; 46:1898-906; PMID:16269605
   PubMed Web of Science ®Google Scholar
• Gaffar SA, Pant KD, Shochat D, Bennett SJ, Goldenberg DM. Experimental studies of tumor radioimmunodetection using antibody mixtures against carcinoembryonic antigen (CEA) and colon-specific antigen-p (CSAp). Int J Cancer 1981; 27:101-5; PMID:7251228; http://dx.doi.org/10.1002/ijc.2910270116
   PubMed Web of Science ®Google Scholar
• Hillairet de Boisferon M, Raguin O, Dussaillant M, Rostene W, Barbet J, Gruaz-Guyon A. Enhanced targeting specificity to tumor cells by simultaneous recognition of two antigens. Bioconjug Chem 2000; 11:452-60; PMID:10898565; http://dx.doi.org/10.1021/bc9901090
   PubMed Web of Science ®Google Scholar
• Hillairet De Boisferon M, Raguin O, Thiercelin C, Dussaillant M, Rostene W, Barbet J, Pelegrin A, Gruaz-Guyon A. Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model. Bioconjug Chem 2002; 13:654-62; PMID:12009958; http://dx.doi.org/10.1021/bc015585g
   PubMed Web of Science ®Google Scholar
• Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW. Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. Cancer 2010; 116:1059-66; PMID:20127951; http://dx.doi.org/10.1002/cncr.24793
   PubMed Web of Science ®Google Scholar
• Munz DL, Alavi A, Koprowski H, Herlyn D. Improved radioimmunoimaging of human tumor xenografts by a mixture of monoclonal antibody F(ab’)2 fragments. J Nucl Med 1986; 27:1739-45; PMID:3772507
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-78; PMID:16467544; http://dx.doi.org/10.1056/NEJMoa053422
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21-8; PMID:19897418; http://dx.doi.org/10.1016/S1470-2045(09)70311-0
   PubMed Web of Science ®Google Scholar
• Kruser TJ, Armstrong EA, Ghia AJ, Huang S, Wheeler DL, Radinsky R, Freeman DJ, Harari PM. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. Int J Radiat Oncol Biol Phys 2008; 72:534-42; PMID:18793955; http://dx.doi.org/10.1016/j.ijrobp.2008.06.1490
   PubMed Web of Science ®Google Scholar
• Koi L, Bergmann R, Bruchner K, Pietzsch J, Pietzsch HJ, Krause M, Steinbach J, Zips D, Baumann M. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. Radiother Oncol 2014; 110:362-9; PMID:24440046; http://dx.doi.org/10.1016/j.radonc.2013.12.001
   PubMed Web of Science ®Google Scholar
• Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma. J Nucl Med 2010; 51:942-50; PMID:20484421; http://dx.doi.org/10.2967/jnumed.109.071290
   PubMed Web of Science ®Google Scholar
• Niu G, Sun X, Cao Q, Courter D, Koong A, Le QT, Gambhir SS, Chen X. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res 2010; 16:2095-105; PMID:20215534; http://dx.doi.org/10.1158/1078-0432.CCR-09-2495
   PubMed Web of Science ®Google Scholar
• Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, Deweese TL, Sgouros G. Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther 2013; 12:2043-54; PMID:23873849; http://dx.doi.org/10.1158/1535-7163.MCT-13-0108
   PubMed Web of Science ®Google Scholar
• Guerard F, Lee YS, Brechbiel MW. Rational design, synthesis, and evaluation of tetrahydroxamic acid chelators for stable complexation of zirconium(IV). Chemistry 2014; 20:5584-91; PMID:24740517; http://dx.doi.org/10.1002/chem.201304115
   PubMed Web of Science ®Google Scholar
• Guerard F, Lee YS, Tripier R, Szajek LP, Deschamps JR, Brechbiel MW. Investigation of Zr(IV) and 89Zr(IV) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging. Chem Commun (Camb) 2013; 49:1002-4; PMID:23250287; http://dx.doi.org/10.1039/c2cc37549d
   PubMed Web of Science ®Google Scholar
• Hand PH, Nuti M, Colcher D, Schlom J. Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens. Cancer Res 1983; 43:728-35; PMID:6848188
   PubMed Web of Science ®Google Scholar
• Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted alpha-particle radiation therapy. Clin Cancer Res 2013; 19:530-7; PMID:23230321; http://dx.doi.org/10.1158/1078-0432.CCR-12-0298
   PubMed Web of Science ®Google Scholar
• Hei TK, Wu LJ, Liu SX, Vannais D, Waldren CA, Randers-Pehrson G. Mutagenic effects of a single and an exact number of alpha particles in mammalian cells. Proc Natl Acad Sci U S A 1997; 94:3765-70; PMID:9108052; http://dx.doi.org/10.1073/pnas.94.8.3765
   PubMed Web of Science ®Google Scholar
• Pugliese M, Durante M, Grossi GF, Monforti F, Orlando D, Ottolenghi A, Scampoli P, Gialanella G. Inactivation of individual mammalian cells by single alpha-particles. Int J Radiat Biol 1997; 72:397-407; PMID:9343105; http://dx.doi.org/10.1080/095530097143176
   PubMed Web of Science ®Google Scholar
• Soyland C, Hassfjell SP. Survival of human lung epithelial cells following in vitro alpha-particle irradiation with absolute determination of the number of alpha-particle traversals of individual cells. Int J Radiat Biol 2000; 76:1315-22; PMID:11057739; http://dx.doi.org/10.1080/09553000050151583
   PubMed Web of Science ®Google Scholar
• Li Y, Abbas Rizvi SM, Blair nee Brown JM, Cozzi PJ, Qu CF, Ow KT, Tam PN, Perkins AC, Russell PJ, Allen BJ. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates. Int J Radiat Oncol Biol Phys 2004; 60:896-908; PMID:15465208; http://dx.doi.org/10.1016/j.ijrobp.2004.04.035
   PubMed Web of Science ®Google Scholar
• Li Y, Cozzi PJ, Qu CF, Zhang DY, Abbas Rizvi SM, Raja C, Allen BJ. Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate. Cancer Lett 2004; 205:161-71; PMID:15036648; http://dx.doi.org/10.1016/j.canlet.2003.10.035
   PubMed Web of Science ®Google Scholar
• Wang J, Abbas Rizvi SM, Madigan MC, Cozzi PJ, Power CA, Qu CF, Morgenstern A, Apostolidis C, Russell PJ, Allen BJ, et al. Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates. Prostate 2006; 66:1753-67; PMID:16955401; http://dx.doi.org/10.1002/pros.20502
   PubMed Web of Science ®Google Scholar
• Milenic DE, Wong KJ, Baidoo KE, Nayak TK, Regino CA, Garmestani K, Brechbiel MW. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. MAbs 2010; 2:550-64; PMID:20716957; http://dx.doi.org/10.4161/mabs.2.5.13054
   PubMed Web of Science ®Google Scholar
• Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, Kahan BD. Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro 1976; 12:180-91; PMID:1262041; http://dx.doi.org/10.1007/BF02796440
   PubMedGoogle Scholar
• Garmestani K, Yao Z, Zhang M, Wong K, Park CW, Pastan I, Carrasquillo JA, Brechbiel MW. Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides. Nucl Med Biol 2001; 28:409-18; PMID:11395314; http://dx.doi.org/10.1016/S0969-8051(00)00203-1
   PubMed Web of Science ®Google Scholar
• Wu C, Kobayashi H, Sun B, Yoo TM, Paik CH, Gansow OA, Carrasquillo JA, Pastan I, Brechbiel MW. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med Chem 1997; 5:1925-34; PMID:9370037; http://dx.doi.org/10.1016/S0968-0896(97)00130-2
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193:265-75; PMID:14907713
   PubMed Web of Science ®Google Scholar
• Dadachova E, Chappell LL, Brechbiel MW. Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol 1999; 26:977-82; PMID:10708314; http://dx.doi.org/10.1016/S0969-8051(99)00054-2
   PubMed Web of Science ®Google Scholar
• Pippin CG, Parker TA, McMurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem 1992; 3:342-5; PMID:1390990; http://dx.doi.org/10.1021/bc00016a014
   PubMed Web of Science ®Google Scholar
• Ray GL, Baidoo KE, Wong KJ, Williams M, Garmestani K, Brechbiel MW, Milenic DE. Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent. Br J Pharmacol 2009; 157:1541-8; PMID:19681874; http://dx.doi.org/10.1111/j.1476-5381.2009.00327.x
   PubMed Web of Science ®Google Scholar